<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194372</url>
  </required_header>
  <id_info>
    <org_study_id>2018_08</org_study_id>
    <secondary_id>2019-A01727-50</secondary_id>
    <nct_id>NCT04194372</nct_id>
  </id_info>
  <brief_title>Signature of the Risk Profile of Mortality in a Hospital Cohort of Patients With Metabolic Diseases</brief_title>
  <acronym>INTEGRA</acronym>
  <official_title>Signature of the Risk Profile of Mortality in a Hospital Cohort of Patients With Metabolic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidemiological studies are usually conducted in the general population in adults without&#xD;
      complications or pathology at baseline. The results obtained are therefore often better&#xD;
      designed for primary prevention use. The prediction of mortality risk in patients with&#xD;
      complications and requiring hospital follow-up is less well known.&#xD;
&#xD;
      The study purpose is to determine a mortality risk profile in a hospital cohort of patients&#xD;
      with pathologies associated with metabolic diseases.&#xD;
&#xD;
      Today the &quot;multimaker&quot; scores based on a panel of biomarkers - have significantly improved&#xD;
      the discriminating power of prediction models existing in many pathologies. It is no longer a&#xD;
      single biomarker that can improve risk prediction but a complete and cross-sectional profile&#xD;
      that is sought after. We aim to establish a personalised mortality risk profile by combining&#xD;
      clinical and biological parameters including metabolomics, genetics, transcriptomics and&#xD;
      epigenomics by high throughput screening of biological samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prediction of the onset of diabetes and metabolic complications, especially&#xD;
      cardiovascular, renal, or hepatic, is a major challenge to optimize the management of this&#xD;
      disease.&#xD;
&#xD;
      Teams from the University Hospital of Lille have developed the Integra cohort study to&#xD;
      identify the clinical and biological determinants of the occurrence of these complications&#xD;
      and the mortality of patients with metabolic disorders.&#xD;
&#xD;
      The aim of the study is to identify clinico-biological determinants that are able to predict&#xD;
      the occurence of death, cardiovascular events as well as hepatic or nephrotic one.&#xD;
&#xD;
      Follow-up data will be collected from National System of Health Data (SNDS) where data&#xD;
      concerning hospitalisations, medical consultations and treatments are registered.&#xD;
&#xD;
      Biological samples are collected at baseline for a large OMICs analysis (metabolomics,&#xD;
      genetics, transcriptomics and epigenomics) that would feed our predictive scoring system.&#xD;
&#xD;
      This project will allow us to describe new models of prediction of metabolic diseases and its&#xD;
      complications, and to offer adapted and personalised methods of management, which can slow&#xD;
      the progression of the disease and improve its prognosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Anticipated">January 2030</completion_date>
  <primary_completion_date type="Anticipated">January 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of death</measure>
    <time_frame>at 10 years</time_frame>
    <description>The number of patients dead according to national database</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of macrovascular complications (composite criteria)</measure>
    <time_frame>at 10 years</time_frame>
    <description>composite criteria: cardiovascular death, myocardial infarction, stroke, coronary revascularization, peripheral revascularization, amputation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization for heart failure</measure>
    <time_frame>at 10 years</time_frame>
    <description>The number of patients that has been hospitalized for heart failure since the end of the study according to national database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of renal microvasculare complications (composite criteria)</measure>
    <time_frame>at 10 years</time_frame>
    <description>composite criteria: renal transplantation, dialysis, GFR &gt;60, Albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of liver complications(composite endpoint)</measure>
    <time_frame>at 10 years</time_frame>
    <description>composite endpoint: hepatic fibrosis, cirrhosis, HCC, death from liver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hemorrhages measured by BARC &gt;3 bleeding</measure>
    <time_frame>at 10 years</time_frame>
    <description>composite endpoint : CABG-related bleeding (Perioperative intracranial bleeding within 48 h / Reoperation after closure of sternotomy for the purpose of controlling bleeding / Transfusion of&lt;5 U whole blood or packed red blood cells within a 48-hperiod / Chest tube output&gt;=2L within a 24-h period)&#xD;
or Fatal Bleeding (Probable fatal bleeding; no autopsy or imaging confirmation butclinically suspicious / Definite fatal bleeding; overt bleeding or autopsy or imagingconfirmation)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>Metabolic Patient</arm_group_label>
    <description>Patients with a metabolic desease, defined as&#xD;
Metabolic Syndrom&#xD;
Diabetic&#xD;
Obese</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, plasma, serum,nail appendage, hair&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with pathologies associated with metabolic disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetic: antecedent - treatment - or glycemia&gt; = 1.26 g / dl - or HbA1C&gt; = 6.5% and&#xD;
             or&#xD;
&#xD;
          -  Obese: BMI&gt; = 30 and or&#xD;
&#xD;
          -  Metabolic syndrome defined AND&#xD;
&#xD;
          -  Patient having given written consent to participate in the study or collection of the&#xD;
             consent of the witness&#xD;
&#xD;
          -  Social insured patient (excluding AME)&#xD;
&#xD;
          -  Patient willing to comply with all procedures of the study and its duration AND&#xD;
&#xD;
        Patient also presenting a pathology among:&#xD;
&#xD;
          -  Cardiology:&#xD;
&#xD;
               -  Coronary patient(history of myocardial infarction, coronary bypass, or coronary&#xD;
                  angioplasty or stenosis greater than 50% on an epicardial vessel documented on&#xD;
                  coronary angiography)&#xD;
&#xD;
               -  Patient with systolic or diastolic heart failure&#xD;
&#xD;
               -  Patient with atrial fibrillation&#xD;
&#xD;
               -  Patient with aortic stenosis (Vmax&gt; 2.5 m / s)&#xD;
&#xD;
               -  Patient with high blood pressure&#xD;
&#xD;
          -  neurology:&#xD;
&#xD;
               -  ischemic stroke&#xD;
&#xD;
               -  intracerebral hemorrhage&#xD;
&#xD;
               -  transient ischemic attack&#xD;
&#xD;
          -  diabetology:&#xD;
&#xD;
               -  Obesity without diabetes&#xD;
&#xD;
               -  Diabetes T2&#xD;
&#xD;
               -  T1 diabetes&#xD;
&#xD;
               -  Monogenic Diabetes / MODY&#xD;
&#xD;
               -  African Diabetes&#xD;
&#xD;
               -  Diabetes secondary to pancreatopathy / liver cirrhosis&#xD;
&#xD;
               -  Diabetes post transplantation / post immunotherapy&#xD;
&#xD;
               -  Diabetes associated with Steinert's disease&#xD;
&#xD;
          -  hepatology: hepatological pathology&#xD;
&#xD;
          -  nephrology: nephrology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unscheduled hospitalization less than 3 months old&#xD;
&#xD;
          -  Ongoing treatment :&#xD;
&#xD;
               -  Cytotoxic chemotherapy&#xD;
&#xD;
               -  Radiotherapy&#xD;
&#xD;
          -  HIV and / or HCV and / or active HBV infection&#xD;
&#xD;
          -  OMS score&gt; = 2&#xD;
&#xD;
          -  Pregnant woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Pattou, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Pattou, MD,PhD</last_name>
    <phone>03 20 44 42 73</phone>
    <phone_ext>+33</phone_ext>
    <email>francois.pattou@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ch Boulogne-Sur-Mer</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hop Cardiologique Chr Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0320445962</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hop Claude Huriez Chr Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0320445962</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic</keyword>
  <keyword>CardioVascular Disease</keyword>
  <keyword>morbi-mortality</keyword>
  <keyword>Hospital Cohort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

